Evidence map›Paper›PMID 26085957›Full record

ArticleJournal of AIDS & clinical research2015

Comparisons of VLP-Based ELISA, Neutralization Assays with Native HPV, and Neutralization Assays with PsV in Detecting HPV Antibody Responses in HIV-Infected Women.

Ping Du, Sarah Brendle, Janice Milici, Fabian Camacho, John Zurlo, Neil Christensen, Craig Meyers

Open access · hybridAbstract read
In one paragraph

Article in Journal of AIDS & clinical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ping DuDepartment of Medicine, The Pennsylvania State University College of Medicine, USA ; Department of Public Health Sciences, The Pennsylvania State University College of Medicine, USA.
Sarah BrendleDepartment of Pathology, The Pennsylvania State University College of Medicine, USA.
Janice MiliciDepartment of Microbiology and Immunology, The Pennsylvania State University College of Medicine, USA.
Fabian CamachoDepartment of Public Health Sciences, The Pennsylvania State University College of Medicine, USA.
John ZurloDepartment of Medicine, The Pennsylvania State University College of Medicine, USA.
Neil ChristensenDepartment of Pathology, The Pennsylvania State University College of Medicine, USA.
Craig MeyersDepartment of Microbiology and Immunology, The Pennsylvania State University College of Medicine, USA.
Pennsylvania State University · US

Funding

Translational Research in Polycystic Ovary SyndromeU54HD034449 · NICHD · VIRGINIA COMMONWEALTH UNIVERSITY · PI ESSAH, PAULINA A · 1997 to 2012
$15.0M
Career Development Program in Women's Health Research at Penn StateK12HD055882 · NICHD · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI WEISMAN, CAROL S · 2007 to 2016
$4.7M
NICHD NIH HHS K12 HD055882NICHD NIH HHS U54 HD034449
6 · The paper itself

Abstract

objectiveHuman papillomavirus (HPV)-associated cancers are important public health problems in HIV-infected people. Assays based on HPV virus-like particles (VLP) and pseudoviruses (PsV) are commonly used to examine HPV antibody responses in HIV-infected people, but neutralization assays with native HPV have not been utilized and a comparison of these three assays is lacking. We evaluated the agreement of assays using VLP, native HPV and PsV in detecting HPV16 and 18 antibodies in HIV-infected women.

methodsThe VLP-based ELISA (VLP-ELISA) was used to detect antibody responses to HPV16 and 18 and cottontail rabbit papillomavirus (CRPV) VLP antigens. Neutralization assays with native HPV (NA-HPV) and with PsV (NA-PsV) were conducted to examine HPV16 or 18 neutralizing antibodies. Intra class correlation coefficients (ICC) and kappa coefficients were used to assess the agreements of seropositivity between the assays.

resultsThe seroprevalence detected by the VLP-ELISA, NA-HPV and NA-PsV in 94 HIV-infected women was 35%, 51% and 27% for HPV16 and 14%, 44% and 21% for HPV18. Cross-reactivity between HPV16 and HPV18 was 0.35, 0.04 and 0.33 (kappa coefficients) for the VLP-ELISA, NA-HPV and NA-PsV. The agreements of seropositivity between the three assays were low. Six women who were HPV16 DNA positive were seropositive by the NA-HPV but only two were HPV16 seropositive by the VLP-ELISA or NA-PsV. One HPV18 DNA positive woman was seropositive by all three assays. Repeated tests indicated excellent reproducibility of the NA-HPV.

conclusionHPV serology results vary across different assays. The NA-HPV appears to be a sensitive and reliable approach in detecting natural HPV antibodies in HIV-infected women. The NA-HPV can be applied in both HPV natural history studies and vaccine studies in HIV-infected people.

Indexed as

ELISAHIV-infected womenHuman papillomavirusNeutralization assayPseudovirusesVirus-like particles

Identifiers

PMID26085957
PMCPMC4467835
OpenAlexW2042573902

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.